Who
Lars Ekman
Director
Company insider
Files Form 4 as: Director and Other, Prothena Corporation; Director, Amarin Corporation; Director, Ultragenyx Pharmaceutical; Director, Spark Therapeutics; Director, Sophiris Bio; Director, Intermune; Director, Ocera Therapeutics; Director, ARYx Therapeutics.
In numbers
- Trades disclosed
- 185
- Buys
- 1
- Sells
- 12
- Bought
- $72K
- Sold
- $15.1M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 18 Sep 2006
- Last trade
- 15 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 May 2026filed 15 May 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,183 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,834 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $101K15,834 at $6.41 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $185K3,411 at $54.15 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $160K2,897 at $55.35 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $373K6,621 at $56.33 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $74K1,303 at $56.98 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $89K1,523 at $58.67 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $59510 at $59.46 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $4,19969 at $60.85 | filing |
| 1 Dec 2022filed 2 Dec 2022 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,834 at $0.00 | filing |
| 1 Dec 2022filed 2 Dec 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $101K15,834 at $6.41 | filing |
| 1 Dec 2022filed 2 Dec 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $601K9,813 at $61.28 | filing |
| 1 Dec 2022filed 2 Dec 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $374K6,021 at $62.12 | filing |
| 1 Nov 2022filed 3 Nov 2022 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,833 at $0.00 | filing |
| 1 Nov 2022filed 3 Nov 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $101K15,833 at $6.41 | filing |
News
Prothena Corporation plc (PRTA) – What Are Analysts Saying About This Stock?PRTA · dailypolitical.com · 20 Oct 2026Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Company StockPRTA · dailypolitical.com · 15 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewPRTA · dailypolitical.com · 12 Oct 2026Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKKGY) Financial ReviewAMRN · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Lars Ekman; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.